Did Inovio Pharmaceuticals Inc (NYSEMKT:INO) find a cure for HIV?
The sudden interest the stock has generated in the investment community is largely based on the publication of a peer reviewed document which highlights Inovio’s successful approach of temporarily combating multiple strains of HIV virus in mice. The process involved in delivery of DNA based mono cell antibodies into the HIV infected mice. These antibodies in turn induces generation of new antibody molecules which posses antigen binding and HIV neutralizing capabilities which in the test lasted for 7 days. The company quoted its CEO to be “particularly excited about this published data” and claims that the early results of these laboratory tests underline the huge and unexplored potential of INO patented “DNA plasmid and electroporation” process.
The company has a market cap of $425 million with over 189 million outstanding shares. The share is down 24% from its prior 52 week high valuation. The share price of this stock has gone up 34% this month and a whopping 330% year to date.
Inovio Pharmaceuticals Inc (NYSEMKT:INO) has been in existence since 1983. It is focusing on generating synthetic vaccines which are used to treat ontological ailments and water and air borne diseases. The Company’s has patented its “SynCon technology” which allows the creation of vaccines which provide protection against multiple strains of viruses that weakens the immune system of human beings. The Company has also patented its use of “electroporation delivery” process which uses small regulated electrical pulses to increase cellular absorption of given vaccine.
Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock is up by 4.19% compared to yesterday’s close of $2.15. The shares were trading at $2.24 per share. In comparison the healthcare index is showing signs of life by going up 0.04% in the same time period. A total of 1.51 million shares of this stock have already been traded across the counter in comparison to 90 day average of 10.4 million transaction volume per day.